English Español

An Observational Study of Efficacy and Utility of Cxbladder Tests in the Identification of Low vs High Risk Patients and the Detection of Urothelial Carcinoma in Patients Presenting With Hematuria


  • Org Study ID: CXB/2019/VA
  • Secondary ID: N/A
  • NTC ID: NCT04943380
  • Sponsor: Pacific Edge Limited


Prospective observational study to validate the performance characteristics and clinical utility of Cxbladder tests in a Veterans Affairs cohort.


Non-invasive, voided urine sample used for both Cxbladder molecular tests, voided urine sample may be used for standard of care testing. Retrospective analysis of data after study completion ensures a de-phasing of study sample analysis from clinical decision making; patient treatment and management.

Multi-site recruitment of patients in Veterans Affairs.Target number of participants up to four sites is around 450 sequentially recruited patients presenting for assessment of hematuria (microscopic or macroscopic) by cystoscopy.

  • Overall Status
  • Start Date
    November 8, 2019
  • Phase
    Not Applicable
  • Study Type


Primary Outcome 1 - Measure: Proportion of participants with bladder cancer who are correctly identified as having cancer (true positives) and no cancer (true negatives) by the Cxbladder test.

Primary Outcome 1 - Timeframe: The outcome measure will be assessed by 6 months after trial completion.

Primary Outcome 2 - Measure: Probability that patients identified as having cancer and no cancer by the Cxbladder test truly have cancer (positive predictive value; PPV), and truly have no cancer (negative predictive value; NPV) respectively.

Primary Outcome 2 - Timeframe: Time Frame: The outcome measure will be assessed by 6 months after trial completion.


  • Hematuria
  • Urothelial Carcinoma


Inclusion Criteria:
Patient is undergoing investigation of recent confirmed hematuria (by either flexible or rigid cystoscopy/TURBT), including hematuria patients referred due to suspicious/positive imaging, in order to determine the presence of urothelial carcinoma.

- Able to provide a voided urine sample of the required minimum volume

- Able to give written consent

- Able and willing to comply with study requirements

- Aged 18 years or older
Exclusion Criteria:
Prior history of bladder malignancy, prostate or renal cell carcinoma

- Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection

- History of glomerulonephritis, nephrosis or other renal inflammatory disorders, recent history of pyelonephritis

- Previous alkylating based chemotherapy

- Pregnancy.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No


Name: Tony Lough, PhD

Role: Study Chair

Affiliation: Pacific Edge Pty Ltd

Overall Contact

Name: Tony Lough, PhD

Phone: (612) 467-5601

Email: mcrisk@umn.edu


Facility Status Contact
Facility: Veterans Medical Research Foundation
San Diego, California 92161
United States
Status: Recruiting Contact: Contact
Anne Jones
858-642-3407 46260
Facility: Minneapolis VA Health Care System
Minneapolis, Minnesota 55417
United States
Status: Recruiting Contact: Principal Investigator
Kyoko Sakamoto
Facility: NWIHCS-Omaha VA Medical Center
Omaha, Nebraska 68105
United States
Status: Recruiting Contact: Contact
Yeng Mua
Facility: Oklahoma City VA Hospital
Oklahoma City, Oklahoma 73104
United States
Status: Recruiting Contact: Principal Investigator
Michael Risk
Facility: Medical University of South Carolina
Charleston, South Carolina 29401
United States
Status: Recruiting Contact: Contact
Holly DeSpiegelaere